ArticleTranslational pediatrics2025
Immune cell reconstitution after allogeneic hematopoietic stem cell transplantation in children with β-thalassemia major.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bringing the rare into sight: applications of haploidentical stem cell transplantation in the treatment of rare diseases.Bone marrow transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for β-thalassemia major (TM). Currently, TM patients undergoing allo-HSCT achieve a survival rate exceeding 90%, with over 80% attaining disease-free survival following treatment at transplant centers worldwide. Sibling donors constitute the most common graft source, and the immune status of pediatric recipients directly influences transplant approach selection, conditioning regimen design, and prognosis. Children with TM exhibit distinct immune states before and after transplantation, yet research on post-transplant immune reconstitution in these patients remains limited. Therefore, this study aims to explore the characteristics of immune reconstitution following allo-HSCT in TM patients, with the goal of providing additional valuable insights for clinical management. This study aimed to investigate the differences in lymphocyte subset reconstitution within 1 year after allo-HSCT in children with TM, evaluate the efficacy of transplantation, and explore factors influencing post-transplant immune cell reconstitution. Methods: We retrospectively analyzed the clinical data of 74 children with TM who underwent allo-HSCT from September 2014 to December 2020 at the Transplantation Center of the Department of Hematology and Oncology, Children's Hospital of Chongqing Medical University to investigate the factors influencing the reconstitution of immune cells after transplantation in children with TM. Results: (I) The results showed that post-transplant cytomegalovirus (CMV) infection, CD34 Conclusions: (I) Post-transplant CMV infection, CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.